197P - Effect of using different antihypertensive drugs on demographic and clinico-pathological characteristics of breast cancer

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Presenter Mehmet Sendur
Citation Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364
Authors M.A. Sendur1, S. Aksoy2, N. Ozdemir1, O. Yazici3, M.B. Akıncı1, D.S. Dede1, B. Yalçın1, N. Zengin1, K. Altundag2
  • 1Department Of Medical Oncology, Yıldırım Beyazıt University, Faculty of Medicine, 06800 - Ankara/TR
  • 2Department Of Medical Oncology, Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 3Medical Oncology, Ankara Numune Education and Research Hospital, 06100 - Ankara/TR



There is limited data about the association of breast cancer and with a selective anti-HT usage. Thus, we aimed to investigate relationship between anti-HT usage and clinico-pathological properties of breast cancer.


Breast cancer patients from 1998 to 2015 were retrospectively analyzed. Patients who were taking oral antihypertensive drugs more than 12 months at the time of breast cancer diagnosis were enrolled as anti-HT users (n = 923), where the patients matched with the same age who were not taking oral anti-HT were included as a control group (n = 923).


A total of 1946 patients with breast cancer were included in this study. 923 patients received an oral anti-HT treatment more than 1 year at the time of breast cancer diagnosis, and 923 patients were considered as non-users. The median follow-up of patients was 57 months. Median age of both group were 57 (23-89). There were no apparent differences in histological type, terms of baseline tumor size, grade, axillary lymph node involvement, extracapsular extension, lymphovascular invasion, type of surgery, menopausal status and hormonal receptor status between both groups. In hypertensive group the history of obesity, hyperlipidemia and diabetes were significantly higher than control group. But perineural invasion positivity and HER2 expression was significantly lower in patients with anti-HT users group (PNI; 12.9% vs 8.8%, P = 0.009, HER2 positivity; 19.5% vs 15.3%, P = 0.02). Significantly lower incidence of T3-T4 tumor and TNM stage were seen in patients with anti-HT users group compared to nonusers. (Stage 3-4; 31.6% vs 33.8%, P = 0.04). In survival analysis, in oral anti-HT users 5-year DFS rate was 80.3%, whereas it was 75.4% in non-users (P = 0.14). Median OS could not be obtained due to low events in both groups but 5-year survival rate in oral anti-HT users was 89.6%, whereas in non-users it was 86.3% (P = 0.01). In oral anti-HT group there was no effect on recurrence and survival between different anti-HT treatments.


In our study, despite higher body mass index and higher incidence of comorbidities in patients with oral anti-HT users, a trend of improvement was observed in terms of DFS and significantly improvement in OS was observed.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.